* If you want to update the article please login/register
Organ transplant recipients of CMV disease is usually treated with a short course of intravenous or oral antiviral therapy. These include CMV gene products targeted at escaping host defense mechanisms, which are often referred to as CMV immune evasion genes [9-11]. Despite an active host immune response, some of these immune evasion genes encode for proteins that can directly interfere with specific steps in the gene expression pathway and thus contribute to viral persistence. ] The CMV UL141 gene product provides protection against a large number of NK cell lines through blocking the expression of NK cell-activating ligand CD155 . The crux of host virus-mediated microRNA interactions mediated by microRNAs is contained by mutations, including virus and countermeasures of host and viral origins miRNAs of host and viral origin and their respective targets. In CMV, a variety of viral microRNAs have been identified. A thorough understanding of the basic pathophysiological changes associated with viral infections has been found. MicroRNAs and CMV is one of the microRNA-mediated host-pathogen interaction is crucial in understanding the basic pathophysiological changes associated with viral infections. Cells infected with CMV that have been engineered to lack the miR-UL112-1 were more susceptible to being killed in a NKG2D-dependent manner by natural killer cells, according to a study by cell lines. CMV can restrict viral replication by restricting viral replication. This is one way in which CMV can limit viral gene production. MiR-UL112-1 down-regulated the expression of CMV genes involved in the company's own replication process, largely by targeting a viral mRNA that regulates viral gene expression needed for acute replication.
Source link: https://clinicaltrials.gov/ct2/show/NCT00677482
Early screening techniques can help breast cancer patients live longer. With the new GlyExo-Capture system, we will isolate glycosylated extracellular vesicles from serum of cancer patients and non-cancer patients, as well as perform miRNA sequencing to find out breast cancer-related genes.
Source link: https://clinicaltrials.gov/ct2/show/NCT05417048
Oral lichen planus is one of the most common mucocutaneous chronic diseases. Several research have investigated miRNA expression as diagnostic and prognostic biomarkers in potentially sick diseased patients from human samples, establishing these miRNAs as risk biomarkers for malignant change with excellent results. Some studies have looked at miRNA in Oral Lichen Planus patients, but not all of them have shown significant differences in miRNA changes, and the role of miRNAs in malignant OLP transformation is under scrutiny. MiR-93 is a form of miRNAs that are part of the miR-106b/u223c25 cluster, and it is a member of the MiR-93 family. miRNA has been shown to have enhanced cell survival, corroborated sphere formation, increased tumor formation, enhanced angiogenesis, elevated endothelial cell function, and prevented apoptosis by targeting integrin-u03b28, a cell death-inducing antigen. In addition, miR-93 overexpression has been found in a wide variety of cancers, including neuroblastoma, non-small cell lung cancer, breast cancer, and ovarian cancer. In addition, an elevated level of miR-93 has been detected in OSCC patients' saliva relative to non-diseased participants. MiR-412-3p has been shown to be highly expressed in extracellular vesicles from oral squamous cell carcinoma patients, which is critical in cancer progression. According to our knowledge, MiRNA-93 and miRNA412-3p haven't been tested in Oral Lichen Planus patients yet, and they have been involved in OSCC patients. In our research, we examine the oncogenicity of miR-93 and miR-412-3p in oral lichen patients for more details on potential new tumor markers in Oral Lichen Planus.
Source link: https://clinicaltrials.gov/ct2/show/NCT05400057
Genetic variants that link to PD can be tested for novel genes and functional variants that indicate disease risk, as well as target genes. Specifically Aim 1: Profile of circulating miRNAs in the serum of PD patients and controls by next-generation sequencing in individual samples. Specific Aim 2: Estimation of predicted miRNAs and PD-related parameters as biomarkers of Parkinson's disease and validation in independent cohorts Aim 3: Identification of genes/genetic variants in miRNA pathways predisposing to PD is expected, and miRNA functional validation will be used to identify novel circulating miRNAs. The project seeks to find new relationships of identified miRNAs with disease-related parameters and establish the role of miRNAs in the physiological pathways in which these parameters are important and in the etiology of PD as the deep phenotype characterization of the study sample.
Source link: https://clinicaltrials.gov/ct2/show/NCT03466723
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions